Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Noxopharm Ltd

Healthcare AU NOX

0.06AUD
-0.006(9.09%)

Last update at 2025-06-20T05:08:00Z

Day Range

0.060.07
LowHigh

52 Week Range

0.060.15
LowHigh

Fundamentals

  • Previous Close 0.07
  • Market Cap19.29M
  • Volume573266
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.60060M
  • Revenue TTM2.34M
  • Revenue Per Share TTM0.008
  • Gross Profit TTM -0.69028M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -15.05637M -18.66681M -9.34675M -0.99957M -12.57258M
Minority interest - - - 0.73M -1.34979M
Net income -15.05637M -18.74414M -24.44703M -22.56130M -11.22279M
Selling general administrative 4.88M 6.58M 5.69M 6.26M 8.11M
Selling and marketing expenses 0.19M 0.10M 0.13M 0.18M 0.33M
Gross profit - - - - 3.75M
Reconciled depreciation 0.15M 0.26M 0.26M 0.24M 0.06M
Ebit -14.95544M -18.58948M -7.16053M 2.47M -11.92168M
Ebitda -14.80091M -18.32796M -6.89881M 2.71M -11.85958M
Depreciation and amortization 0.15M 0.26M 0.26M 0.24M 0.06M
Non operating income net other - - - - -
Operating income -14.95544M -18.58948M -7.16053M 2.47M -11.92168M
Other operating expenses 16.60M 15.21M 20.21M 16.37M 15.68M
Interest expense 0.04M 0.08M 2.19M 3.47M 0.65M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 4.49M 0.05M 5.06M 7.02M 0.19M
Net interest income 0.04M -0.03039M -2.04675M -3.45554M -0.46421M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.60M 0.08M 15.10M 21.56M -1.34979M
Total revenue 6.07M 5.45M 5.75M 8.34M 3.94M
Total operating expenses 16.60M 15.21M 20.21M 16.37M 15.68M
Cost of revenue - - - - -
Total other income expense net 1.50M -0.07734M -2.18622M -3.46685M -0.65090M
Discontinued operations - - - - -
Net income from continuing ops -15.05637M -18.66681M -9.34675M -0.99957M -12.57258M
Net income applicable to common shares -15.05637M -18.66681M -9.34675M -0.27209M -11.22279M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 6.78M 10.13M 26.59M 47.85M 20.07M
Intangible assets - - - - 0.00000M
Earning assets - - - - -
Other current assets 0.04M 0.00000M 0.46M 0.07M 0.06M
Total liab 1.29M 1.06M 2.48M 7.08M 7.19M
Total stockholder equity 5.50M 9.07M 24.12M 40.78M 12.87M
Deferred long term liab - - - - -
Other current liab 0.60M 0.51M 1.31M 0.45M 0.31M
Common stock 74.64M 74.64M 74.64M 72.62M 41.63M
Capital stock - 74.64M 74.64M 72.62M 41.63M
Retained earnings -70.07034M -72.06052M -58.80303M -40.33330M -31.46636M
Other liab - 0.09M 0.19M 0.15M 0.10M
Good will - - - - -
Other assets - 0.00000M 0.12M 0.12M 0.35M
Cash 2.32M 3.01M 14.01M 26.80M 7.10M
Cash and equivalents - 0.00000M 8.00M 10.00M -
Total current liabilities 1.25M 0.96M 2.28M 6.81M 6.69M
Current deferred revenue - - - - -
Net debt -2.31993M -3.00867M -13.85004M -26.44648M -2.10009M
Short term debt - 0.00000M 0.16M 0.23M 4.59M
Short long term debt - - - - 4.34M
Short long term debt total - - 0.16M 0.35M 5.00M
Other stockholder equity - 6.50M 8.29M 8.49M 2.71M
Property plant equipment - 0.00741M 0.22M 0.48M 0.85M
Total current assets 4.77M 9.16M 20.83M 32.97M 12.33M
Long term investments - 0.96M 5.42M 14.27M 6.54M
Net tangible assets - 9.07M 24.12M 40.78M 12.87M
Short term investments - - - - -
Net receivables 2.40M 6.08M 5.21M 5.80M 4.65M
Long term debt - - - - -
Inventory - - 1.15M 0.31M 0.52M
Accounts payable 0.65M 0.45M 0.81M 6.13M 1.79M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.93M 6.50M 8.29M 8.49M 2.71M
Additional paid in capital - - - - -
Common stock total equity - - - - 41.63M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.12M 0.12M 0.35M
Deferred long term asset charges - - - - -
Non current assets total 2.02M 0.97M 5.76M 14.88M 7.74M
Capital lease obligations - - 0.16M 0.35M 0.66M
Long term debt total - 0.00000M 0.00000M 0.12M 0.41M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 0.12M - 0.23M 0.34M -0.00320M
Change to liabilities -1.07874M -4.33445M 4.34M 0.77M 0.60M
Total cashflows from investing activities 0.12M 0.12M 0.23M 0.34M -0.00320M
Net borrowings -0.17810M -0.22914M -0.24482M 3.84M 3.84M
Total cash from financing activities -0.17810M 0.98M 28.32M 14.99M 0.07M
Change to operating activities -0.18126M -0.07839M 0.19M 0.15M 0.05M
Net income -15.05637M -18.74414M -11.53297M -0.27209M -11.22279M
Change in cash -11.00199M -12.78512M 19.70M 4.19M -9.70397M
Begin period cash flow 14.01M 26.80M 7.10M 2.91M 12.61M
End period cash flow 3.01M 14.01M 26.80M 7.10M 2.91M
Total cash from operating activities -10.94635M -18.48263M -8.85044M -11.13796M -9.77576M
Issuance of capital stock - 1.20M 30.10M 11.01M 0.07M
Depreciation 0.15M 0.26M 0.26M 0.24M 0.06M
Other cashflows from investing activities 0.12M 0.12M 0.23M 0.34M 0.00320M
Dividends paid - - - -9.69698M -
Change to inventory 1.15M -0.83498M 0.21M 0.18M 0.57M
Change to account receivables -0.47743M 0.18M -1.13977M -4.72265M -0.03776M
Sale purchase of stock 0.00000M 1.20M -1.52835M -0.78568M 0.07M
Other cashflows from financing activities -0.17810M -0.22914M -0.24482M 20.05M -0.00320M
Change to netincome 4.55M 9.74M -3.36711M -7.48069M -0.44856M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00300M 0.00640M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 5.12M 5.95M 4.76M 3.84M 3.94M
Stock based compensation - - - - -
Other non cash items - 18.48M 9.09M 0.03M 11.16M
Free cash flow -10.94635M -18.48263M -8.85044M -0.00300M -0.00640M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
NOX
Noxopharm Ltd		 -0.006 9.09% 0.06 - - 8.23 4.46 -1.1582
CSL
CSL Ltd		 1.50 0.63% 240.21 28.64 32.15 7.65 4.04 5.81 18.03
TLX
Telix Pharmaceuticals Ltd		 -0.08 0.32% 24.92 166.67 57.47 10.68 14.73 10.52 89.03
MSB
Mesoblast Ltd		 -0.03 1.80% 1.64 - 454.55 367.78 2.98 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.10 0.80% 12.54 11.61 75.76 7.37 4.49 6.61 8.03

Reports Covered

Stock Research & News

View All

Profile

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. Noxopharm Limited was incorporated in 2015 and is based in Glenhaven, Australia.

Noxopharm Ltd

60 Linksley Avenue, Glenhaven, NSW, Australia, 2156

Key Executives

Name Title Year Born
Dr. Gisela Mautner CEO, Exec. MD, Chief Medical Officer & Director NA
Mr. Shawn Van Boheemen Chief Financial Officer NA
Ms. Jeanette Bell Ph.D. Chief Operating Officer NA
Dr. John Wilkinson B.Sc., Ph.D. Chief Scientific Officer of Oncology NA
Dr. Olivier Laczka B.S., M.Sc., Ph.D. Chief Scientific Officer of Inflammation NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Dr. Gisela Mautner CEO, Executive MD & Director NA
Mr. Shawn Van Boheemen FCPA Chief Financial Officer NA
Mr. David James Franks BEc, C.A., F Fin, J.P. Company Secretary 1970
Dr. Gisela Mautner CEO, Executive MD & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.